[68Ga]Ga-RM26与[68Ga]Ga-PSMA-617 PET/CT在前列腺癌疑似患者中的前瞻性对比研究
该前瞻性研究纳入207例疑似前列腺癌参与者,均行[68Ga]Ga-RM26与[68Ga]Ga-PSMA-617 PET/CT,以病理为参考标准。结果示[68Ga]Ga-PSMA-617检测临床显著前列腺癌的AUC高于[68Ga]Ga-RM26,但[68Ga]Ga-RM26对低风险前列腺癌显像有优势。
要点
- 207例疑似前列腺癌中125例为癌、82例为良性前列腺增生。
- [68Ga]Ga-PSMA-617检测前列腺癌AUC 0.91,高于[68Ga]Ga-RM26的0.54。
- [68Ga]Ga-RM26对Gleason评分6分前列腺癌敏感性更高但特异性仅20.73%。
核心结论
- 本前瞻性研究提供证据表明[68Ga]Ga-PSMA-617 PET/CT在检测更多临床显著前列腺癌方面准确性优于[68Ga]Ga-RM26 PET/CT。
- [68Ga]Ga-RM26 PET/CT在低风险前列腺癌显像方面显示出优势。
研究设计与样本
- 前瞻性研究纳入207例疑似前列腺癌参与者,每例均行[68Ga]Ga-RM26与[68Ga]Ga-PSMA-617 PET/CT。
- 以病理标本为参考标准对比PET/CT显像。
主要发现
- 207例中125例为前列腺癌,82例诊断为良性前列腺增生。
- [68Ga]Ga-RM26与[68Ga]Ga-PSMA-617 PET/CT检测临床显著前列腺癌的敏感性和特异性差异有统计学意义。
- 检测前列腺癌的ROC曲线下面积(AUC):[68Ga]Ga-RM26 PET/CT为0.54,[68Ga]Ga-PSMA-617 PET/CT为0.91。
- 检测临床显著前列腺癌的AUC分别为[68Ga]Ga-RM26 0.51 vs [68Ga]Ga-PSMA-617 0.93。
- [68Ga]Ga-RM26 PET/CT对Gleason评分(GS)=6前列腺癌的敏感性高于[68Ga]Ga-PSMA-617 PET/CT(p=0.03),但特异性差(20.73%)。
关键数值与推荐
- PSA<10 ng/mL组中,[68Ga]Ga-RM26 PET/CT vs [68Ga]Ga-PSMA-617 PET/CT的敏感性为60.00% vs 80.30%(p=0.12),特异性为23.26% vs 88.37%(p=0.000),AUC为0.524 vs 0.822(p=0.000)。
- [68Ga]Ga-RM26 PET/CT在GS=6标本(p=0.04)和低风险组(p=0.01)中SUVmax显著更高,其摄取不随PSA水平、GS或临床分期增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate-specific membrane antigen (PSMA)-based PET/CT imaging has limitations in the diagnosis of prostate cancer (PCa). We recruited 207 participants with suspicious PCa to perform PET/CT imaging with radiolabeled gastrin-releasing peptide receptor (GRPR) antagonist, [68Ga]Ga-RM26, and compare with [68Ga]Ga-PSMA-617 and histopathology. METHODS: Every participant with suspicious PCa was scanned with both [68Ga]Ga-RM26 and [68Ga]Ga-PSMA-617 PET/CT. PET/CT imaging was compared using pathologic specimens as a reference standard. RESULTS: Of the 207 participants analyzed, 125 had cancer, and 82 were diagnosed with benign prostatic hyperplasia (BPH). The sensitivity and specificity of [68Ga]Ga-RM26 and [68Ga]Ga-PSMA-617 PET/CT imaging differed significantly for detecting clinically significant PCa. The area under the ROC curve (AUC) was 0.54 for [68Ga]Ga-RM26 PET/CT and 0.91 for [68Ga]Ga-PSMA-617 PET/CT in detecting PCa. For clinically significant PCa imaging, the AUCs were 0.51 vs. 0.93, respectively. [68Ga]Ga-RM26 PET/CT imaging had higher sensitivity for PCa with Gleason score (GS) = 6 (p = 0.03) than [68Ga]Ga-PSMA-617 PET/CT but poor specificity (20.73%). In the group with PSA < 10 ng/mL, the sensitivity, specificity, and AUC of [68Ga]Ga-RM26 PET/CT were lower than [68Ga]Ga-PSMA-617 PET/CT (60.00% vs. 80.30%, p = 0.12, 23.26% vs. 88.37%, p = 0.000, and 0.524 vs. 0.822, p = 0.000, respectively). [68Ga]Ga-RM26 PET/CT exhibited significantly higher SUVmax in specimens with GS = 6 (p = 0.04) and in the low-risk group (p = 0.01), and its uptake did not increase with PSA level, GS, or clinical stage. CONCLUSION: This prospective study provided evidence for the superior accuracy of [68Ga]Ga-PSMA-617 PET/CT over [68Ga]Ga-RM26 PET/CT in detecting more clinically significant PCa. [68Ga]Ga-RM26 PET/CT showed an advantage for imaging low-risk PCa.
引用
- Gao X, Tang Y, Chen M, et al. A prospective comparative study of [68Ga]Ga-RM26 and [68Ga]Ga-PSMA-617 PET/CT imaging in suspicious prostate cancer. Eur J Nucl Med Mol Imaging. 2023. PMID: 36811661. doi:10.1007/s00259-023-06142-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。